Improve Safety in Polymedication by Managing Drug-Drug-Gene Interactions

Informations projet

SafePolyMed

N° de convention de subvention: 101057639

DOI 10.3030/101057639

Date de signature de la CE 23 Mai 2022

Date de début 1 Juin 2022

Date de fin 30 Novembre 2025

Financé au titre de

• Health

Coût total € 5 650 444,56

Contribution de l’UE € 5 650 442,81

Coordonné par

UNIVERSITAT DES SAARLANDES
Germany

Livrables

Websites, patent fillings, videos etc. (2)

Public Project Website
Audio-visual material

Documents, reports (5)

Selection of clinically relevant compounds
English-Estonian dictionary
Content for the training curriculum for empowerment of patients in pharmacology and drug safety
Design and implementation of the SafePolyMed platform for the analysis of the retrospective data
Patient engagement Hub: setup of a priority setting network of different patient organisations

Publications

Peer reviewed articles (1)

Genetic predictors of lifelong medication-use patterns in cardiometabolic diseases

Auteurs: Tuomo Kiiskinen, Pyry Helkkula, Kristi Krebs, Juha Karjalainen, Elmo Saarentaus, Nina Mars, Arto Lehisto, Wei Zhou, Mattia Cordioli, Sakari Jukarainen, Joel T. Rämö, Juha Mehtonen, Kumar Veerapen, Markus Räsänen, Sanni Ruotsalainen, Mutaamba Maasha, F
Publié dans: Nature Medicine, Numéro 29, 2023, ISSN 1078-8956
Éditeur: Nature Medicine (Nat Med)
DOI: 10.1038/s41591-022-02122-5